Our data suggest a novel therapeutic indicator for evaluating the sensitivity of anti‐PD‐1 or anti‐CTLA‐4 treatments in patients with cancer, and further studies should be applied to validate these results in clinical trials. Here, CTLA4 is linked to cancer.